Shuichi Hironaka, MD, PhD, discusses the efficacy of a phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line treatment of patients with advanced gastric cancer during the 2020 Gastrointestinal Cancers Symposium.
Shuichi Hironaka, MD, PhD
Advertisement
Articles by Shuichi Hironaka, MD, PhD
Advertisement
Latest Updated Articles
Phase I/II Study Demonstrates Good Efficacy for Gastric CancerPublished: April 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
2
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
3
Beyond SC Daratumumab: Emerging Therapeutic Approaches for Smoldering Myeloma
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
